TL;DR
A drug meant to clear the worn-out "zombie" cells that build up with age has, in a randomized trial against placebo, reversed scarring in human livers. In 31 patients with fatty-liver scarring, nearly half of those on the two-drug combination improved by at least one stage of scarring, against 1 in 14 on placebo. That makes these drugs, called senolytics, one of the very few anti-aging drug classes with randomized human evidence that they change real tissue. The catch is money, not biology: both drugs are cheap generics, and no company has paid for the big trial that would turn the result into a treatment. Meanwhile a startup's skin cream is heading into a hair-loss study. The evidence so far is organ by organ, not a whole-body fountain of youth.
Below the line, for paid subscribers: The full story: where it stands, how we got here and what's dated next; our Odds board on 6 milestones, starting with "First human data from Rubedo's hair-loss study by 2027"; and every source.